Resources

Patients in the UK now have access to MRIdian, a technology from GenesisCare which combines magnetic resonance imaging (MRI) with precise radiotherapy beams. Globally, the technology has been used to treat 7,000 patients, with the greatest potential benefit being seen...

After Novartis’ near $10 billion buyout of The Medicines Company, and with it the biotech’s leading heart drug hopeful, many thought cardiovascular therapies were hot again.

Beta Bionics has secured breakthrough device designation status from the US Food and Drug Administration (FDA) for its iLet Bionic Pancreas System. iLet Bionic Pancreas is a wearable, autonomous system that leverages artificial intelligence (AI) and machine...

Roche has secured CE mark for its smartphone app that allows users to measure blood glucose level without the need of a meter. Known as Accu-Chek SugarView, the app determines blood glucose ranges by taking photos with the smartphone camera. The company said that the...

Researchers have identified several families whose members suffer from similar autoimmune symptoms and discovered they all had irregularities in RIPK1, a gene that makes a key protein in the mediation of cell death and inflammation. The findings could...

Leo Pharma’s tralokinumab has hit all the primary and secondary endpoints in its three pivotal trials. The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year, but the lack of numbers shared publicly make it impossible to...

US-based Nihon Kohden has introduced a new portable vital signs monitoring tool with customisable early warning scoring. Designed for outpatient facilities, the Life Scope SVM-7200 Series measures blood oxygen, blood pressure and temperature. The newly launched device...

Seattle Genetics has shared more of the tucatinib data it hopes will win it approval in HER2-positive breast cancer. The pivotal trial linked the tyrosine kinase inhibitor to reduced risk of progression and death in patients with and without brain metastases, leading...

MacroGenics presented new, phase 3 breast cancer data from its HER2-targeting antibody margetuximab as it works to put the finishing touches on the drug’s approval application to the FDA in the final weeks of this year.

The perennial drug pricing debate has reached a fever pitch, as loud as it’s ever been over the past few decades. Politicians on both sides are bashing the drug industry with the typical talking points about exorbitant prices, countered of course by the expected...

The US Food and Drug Administration (FDA) has approved Aptar Group’s Unidose Liquid System to treat acute repetitive seizures in those with epilepsy. Claimed to be the first and only nasal rescue treatment for seizures, Aptar’s Unidose Liquid System is a...

IFM Therapeutics has raised $55.5 million to launch its third drug subsidiary as well as an incubator, both of which are focused on developing new therapies for inflammatory diseases and cancers. Read more. The post IFM Lands $55.5M to Launch NewCo Quattro...

Today Alkermes announced its acquisition of Rodin Therapeutics, a leader in the field of synaptic dysfunction and neuronal epigenetics. Read more. The post Thinking Boldly: Alkermes Acquires Rodin Therapeutics appeared first on Atlas Venture.

Neuroscience has had a tough run of news lately. With Amgen deprioritizing neuro this year, Pfizer doing the same last year, and others like BMS, GSK, and AZ cutting back on CNS a few years earlier, it would seem dark times for neuroscience R&D. Add...

Brian MacDonald’s original foray into treating iron dysregulation by injecting hepcidin, a small peptide hormone key for iron homeostasis, didn’t quite get off the ground. This time, the former GSK executive is taking a fresh approach — by regulating...

The OVM6948 provides images from the smallest parts of human anatomy, and for a variety of procedures.

Biomedical engineers look to fix the patient, not the artificial limb.

A magnet-impregnated rubber sheet was designed to detect force and contact, mimicking human skin.

The Call for Code IoT competition is preparing laypeople and professionals alike for natural disasters.

At the low end of the IoT spectrum, simple, commoditized solutions often deliver poorly implemented user interfaces. This article examines various problems that result from a inadequately designed UI for IoT products.

Due to meetings in London on a Friday and in Dortmund on the following Monday, I spent the weekend in London.  As I walked the streets appreciating its history, I could not help but think of the history of medicine, as well.  Images of leeches and...

Building a leading gene therapy pipeline in under two years (and a lot of air miles): how to persevere and make the calls that matter. Throughout a career in business development I’ve sat at every seat at the negotiating table, but I count my experience building...

For decades, preparing for climate change felt like waiting for a meteor to hit: Sure, it could happen. But the threat didn’t feel imminent compared to the challenges businesses faced. But concern has been rising as more communities and companies across the...

Nearly two years ago, Nessan Bermingham, Ph.D., handed the reins of Intellia Therapeutics over to John Leonard, M.D., the R&D chief who had built the company alongside him. After a break, he landed at Atlas Venture, the VC firm that helped launch...

The scientific founder and CEO of Cambridge startup Dyne Therapeutics has hired a new CEO — a former CFO with experience in public stock offerings. Read more. The post With eyes on IPO, muscular dystrophy startup names new CEO appeared first on Atlas Venture.